Please login to the form below

Not currently logged in

Novartis licenses tuberculosis R&D to TB Alliance

Novartis buildingIncludes drugs to tackle resistant forms of the disease

UDG sells stake in UniDrug

UDG HealthcareAlliance Boots will take over full control of supply chain specialist

NICE backs Celgene’s Revlimid in bone marrow disorder

Celgene Revlimid lenalidomideRecommends that drug can be used on NHS to treat myelodysplastic syndromes

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

US regulator Food and Drug Administrator FDAFull FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

Chugai soars on Roche buyout rumours

chugai logoReports circulating that Swiss company is poised to make $10bn offer

Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

Eisai Fycompa perampanel epilepsyGerman cost-effectiveness body once again says Fycompa should not be reimbursed

AstraZeneca launches diabetes portal in Germany is designed to educate patients and families

FDA approves Biogen Idec's long-acting MS therapy

Biogen Idec buildingPlegridy gets US nod just weeks after EU approval

old world mapHistory rhymes: modern globalisation trends mirror the past

Recent events are an echo of the late 19th century

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Virgo Health

From insightful consultancy to flawless campaign execution, we apply our unrivalled blend of exceptional quality, experience, innovation and multi-channel award-winning...

Latest intelligence

3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...
Exploring MINT: Part 2 - Indonesia
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...